Biogen opted out of the development of INO582 ... Bamboo/Pfizer, and Stride Bio/Sarepta. BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback ...

For 13 years, Marks led the FDA's Center for Biologics Evaluation and Research, the department in charge of reviewing and approving vaccines, genetic medicines and cell therapies.Please watch the ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the ...

CAMBRIDGE, Mass., March 31, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31 ...

Shares of NASDAQ:SRPT opened at $61.91 on Monday. The firm has a market capitalization of $6.01 billion, a price-to-earnings ratio of 49.53 and a beta of 0.79. The company has a debt-to-equity ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $190.00. The company’s shares closed last Friday at ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (BMV:SRPT) from Outperform to Sector Perform. There are 956 funds or institutions reporting ...

Now that the month is closed, I can state I went three for three in those projections during March. The VIX did indeed move over 25 for the first time during the year, cresting to just over 29 ...